EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM). - Kaiser, Martin; Suvannasankha, Attaya; Lee, Dawn; Dlotko, Ewa; Macleod, Paul; Boytsov, Natalie; Crossman-Morgan, Christina-Jane; Jadhav, Vinay; Kazeem, Gbenga; Lloyd, Connor; Purser, Molly; Riemer, Justin; et al. (Value in Health, 2025)